Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 15, 2025 | May 16, 2025 |
| Huron Consulting Group Inc.HURN · Entity 4332 | Director | April 01, 2020 | April 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 15, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,575 |
Ending reported balance
After 2025-05-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-05-15 · Sale · Disposed 35 · Balance 5,680 F1: This transaction was executed in multiple trades at prices ranging from $136.07 to $136.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Row 2 · 2025-05-15 · Sale · Disposed 81 · Balance 5,599 F2: This transaction was executed in multiple trades at prices ranging from $137.19 to $138.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Row 3 · 2025-05-15 · Sale · Disposed 24 · Balance 5,575 F3: This transaction was executed in multiple trades at prices ranging from $139.02 to $139.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $136.07 to $136.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $137.19 to $138.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024.
F3: This transaction was executed in multiple trades at prices ranging from $139.02 to $139.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024.
Huron Consulting Group Inc.
Report date April 01, 2020 · Filed April 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,719 |
Reported balance
After 2020-04-01 transaction · row 1
1 source rowRow 1 · 2020-04-01 · Sale · Disposed 760 · Balance 17,719 F1: Automatic sale pursuant to a 10b5-1 plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic sale pursuant to a 10b5-1 plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 16, 2025 20:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 24 | $139.05 | $3,337.20 |
DisclosureSEC source: 0001127602-25-014711 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,575 F3 · price: This transaction was executed in multiple trades at prices ranging from $139.02 to $139.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 81 | $137.68 | $11,152.08 |
DisclosureSEC source: 0001127602-25-014711 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,599 F2 · price: This transaction was executed in multiple trades at prices ranging from $137.19 to $138.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 35 | $136.32 | $4,771.20 |
DisclosureSEC source: 0001127602-25-014711 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,680 F1 · price: This transaction was executed in multiple trades at prices ranging from $136.07 to $136.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 7 | $145.54 | $1,018.78 |
DisclosureSEC source: 0001127602-25-014486 · form4.xml · nonDerivative · entry 5 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,715 F5 · price: This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 7 | $143.77 | $1,006.39 |
DisclosureSEC source: 0001127602-25-014486 · form4.xml · nonDerivative · entry 4 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,722 F4 · price: This transaction was executed in multiple trades at prices ranging from $143.70 to $143.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 14 | $141.85 | $1,985.90 |
DisclosureSEC source: 0001127602-25-014486 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,729 F3 · price: This transaction was executed in multiple trades at prices ranging from $141.80 to $141.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 21 | $140.78 | $2,956.38 |
DisclosureSEC source: 0001127602-25-014486 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,743 F2 · price: This transaction was executed in multiple trades at prices ranging from $140.52 to $141.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 91 | $139.95 | $12,735.45 |
DisclosureSEC source: 0001127602-25-014486 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,764 F1 · price: This transaction was executed in multiple trades at prices ranging from $139.47 to $140.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 96 | $236.78 | $22,730.88 |
DisclosureSEC source: 0001127602-24-015691 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,855 F3 · price: This transaction was executed in multiple trades at prices ranging from $236.36 to $237.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 113 | $235.61 | $26,623.93 |
DisclosureSEC source: 0001127602-24-015691 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,951 F2 · price: This transaction was executed in multiple trades at prices ranging from $235.35 to $236.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 123 | $234.72 | $28,870.56 |
DisclosureSEC source: 0001127602-24-015691 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,064 F1 · price: This transaction was executed in multiple trades at prices ranging from $234.27 to $235.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,311 | $228.41 Strike: $228.41 | $299,445.51 |
DisclosureSEC source: 0001127602-24-015518 · form4.xml · derivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,311 Underlying: Common Stock · 1,311 shares Expires 2034-05-13 F2 · shares: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 559 | $228.41 | $127,681.19 |
DisclosureSEC source: 0001127602-24-015518 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,187 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,669 | $192.36 Strike: $192.36 | $321,048.84 |
DisclosureSEC source: 0001127602-23-015852 · form4.xml · derivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires 2033-05-15 F2 · shares: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015852 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,628 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2023 Filed May 15, 2023 18:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 288 | $193.43 | $55,707.84 |
DisclosureSEC source: 0001127602-23-015523 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,964 F1 · shares: This sale occurred pursuant to a 10b5-1 trading plan. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,582 | $222.31 Strike: $222.31 | $351,694.42 |
DisclosureSEC source: 0001127602-22-014431 · form4.xml · derivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582 Underlying: Common Stock · 1,582 shares Expires 2032-05-11 F2 · shares: The Stock Options become exercisable upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014431 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,252 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 09, 2022 Filed May 11, 2022 19:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 8 | $238.06 | $1,904.48 |
DisclosureSEC source: 0001127602-22-014132 · form4.xml · nonDerivative · entry 7 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,677 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 09, 2022 Filed May 11, 2022 19:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 15 | $235.23 | $3,528.45 |
DisclosureSEC source: 0001127602-22-014132 · form4.xml · nonDerivative · entry 6 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,685 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 09, 2022 Filed May 11, 2022 19:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 13 | $232.79 | $3,026.27 |
DisclosureSEC source: 0001127602-22-014132 · form4.xml · nonDerivative · entry 5 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 09, 2022 Filed May 11, 2022 19:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 15 | $231.88 | $3,478.20 |
DisclosureSEC source: 0001127602-22-014132 · form4.xml · nonDerivative · entry 4 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,713 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 09, 2022 Filed May 11, 2022 19:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 15 | $230.33 | $3,454.95 |
DisclosureSEC source: 0001127602-22-014132 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,728 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 09, 2022 Filed May 11, 2022 19:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 88 | $229.90 | $20,230.95 |
DisclosureSEC source: 0001127602-22-014132 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,743 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $229.43 to $230.045. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2022 Filed May 11, 2022 19:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 24 | $228.62 | $5,486.88 |
DisclosureSEC source: 0001127602-22-014132 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,831 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $228.22 to $228.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,539 | $0.00 Strike: $164.24 | $0.00 |
DisclosureSEC source: 0001127602-21-024662 · form4.xml · derivative · entry 5 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,539 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 983 | $442.99 | $435,457.50 |
DisclosureSEC source: 0001127602-21-024662 · form4.xml · nonDerivative · entry 4 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,855 F2 · price: This transaction was executed in multiple trades at prices ranging from $442.725 to $443.265. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,556 | $442.16 | $687,999.72 |
DisclosureSEC source: 0001127602-21-024662 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,838 F1 · price: This transaction was executed in multiple trades at prices ranging from $441.67 to $442.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 2,539 | $164.24 | $417,005.36 |
DisclosureSEC source: 0001127602-21-024662 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Sep 1, 2021 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024662 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,855 Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1 | $323.29 | $323.29 |
DisclosureSEC source: 0001127602-21-016416 · form4.xml · nonDerivative · entry 5 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,355 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 110 | $321.06 | $35,316.13 |
DisclosureSEC source: 0001127602-21-016416 · form4.xml · nonDerivative · entry 4 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,356 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $320.79 to $321.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 174 | $320.19 | $55,713.20 |
DisclosureSEC source: 0001127602-21-016416 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,466 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $319.76 to $320.685. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 56 | $319.42 | $17,887.76 |
DisclosureSEC source: 0001127602-21-016416 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,640 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $319.23 to $319.695. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 30 | $316.75 | $9,502.35 |
DisclosureSEC source: 0001127602-21-016416 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,696 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $342.55 | $0.00 |
DisclosureSEC source: 0001127602-21-016111 · form4.xml · derivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-07 F2 · shares: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016111 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,726 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 06, 2021 Filed May 7, 2021 17:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $338.98 | $203,386.02 |
DisclosureSEC source: 0001127602-21-015816 · form4.xml · nonDerivative · entry 4 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,371 F4 · price: This transaction was executed in multiple trades at prices ranging from $338.71 to $339.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 06, 2021 Filed May 7, 2021 17:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 288 | $338.06 | $97,362.29 |
DisclosureSEC source: 0001127602-21-015816 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,971 F3 · price: This transaction was executed in multiple trades at prices ranging from $338.05 to $338.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 06, 2021 Filed May 7, 2021 17:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 910 | $336.84 | $306,522.22 |
DisclosureSEC source: 0001127602-21-015816 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,259 F2 · price: This transaction was executed in multiple trades at prices ranging from $336.55 to $337.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 06, 2021 Filed May 7, 2021 17:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,572 | $336.06 | $528,290.25 |
DisclosureSEC source: 0001127602-21-015816 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,169 F1 · price: This transaction was executed in multiple trades at prices ranging from $335.54 to $336.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 23, 2020 Filed Feb 2, 2021 16:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003437 · form5.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,741 Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 70 | $220.78 | $15,454.52 |
DisclosureSEC source: 0001127602-20-025127 · form4.xml · nonDerivative · entry 4 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,441 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $220.725 to $220.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,288 | $220.15 | $283,553.59 |
DisclosureSEC source: 0001127602-20-025127 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,511 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $219.72 to $220.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 585 | $219.27 | $128,275.47 |
DisclosureSEC source: 0001127602-20-025127 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,799 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $218.63 to $219.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2020 Filed Sep 15, 2020 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-025127 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,384 Read SEC document |
| May 22, 2020 Filed May 26, 2020 18:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 83 | $174.75 | $14,504.25 |
DisclosureSEC source: 0001127602-20-017883 · form4.xml · nonDerivative · entry 3 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 22, 2020 Filed May 26, 2020 18:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 255 | $173.87 | $44,337.87 |
DisclosureSEC source: 0001127602-20-017883 · form4.xml · nonDerivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,967 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $173.575 to $174.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 22, 2020 Filed May 26, 2020 18:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 603 | $173.01 | $104,326.06 |
DisclosureSEC source: 0001127602-20-017883 · form4.xml · nonDerivative · entry 1 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,222 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $172.46 to $173.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2020 Filed May 12, 2020 17:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,539 | $0.00 Strike: $164.24 | $0.00 |
DisclosureSEC source: 0001127602-20-016227 · form4.xml · derivative · entry 2 MASSARO GEORGE · CIK 0001221496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539 Underlying: Common Stock · 2,539 shares Expires 2030-05-11 F2 · derivative.exercise_date: The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.